世界のHIVワクチン市場規模・現状・予測（2021年-2027年）

• 英文タイトル：Global HIV Vaccines Market Size, Status and Forecast 2021-2027

• レポートコード：QYR2104Z2861 • 出版社/出版日：QYResearch / 2021年4月 ※2025年版があります。お問い合わせください。 • レポート形態：英文、PDF、99ページ • 納品方法：Eメール（納期：3日） • 産業分類：医薬品、ヘルスケア

• 販売価格（消費税別）

Single User	￥546,000 (USD3,900)	▷ お問い合わせ
Multi User/Five User	￥819,000 (USD5,850)	▷ お問い合わせ
Enterprise License（同一法人内共有可）	￥1,092,000 (USD7,800)	▷ お問い合わせ

• ご注文方法：お問い合わせフォーム記入又はEメールでご連絡ください。
• お支払方法：銀行振込（納品後、ご請求書送付）

---

レポート概要

---

QYResearch社発行の本調査資料では、HIVワクチンのグローバル市場（2016年～2027年）について調べ、市場動向、主要企業の市場シェア、種類別市場規模（フェーズI、フェーズII、フェーズIII）、用途別市場規模（研究所、その他）、主要地域別市場規模（北米、アメリカ、ヨーロッパ、アジア、日本、中国、韓国、インド、東南アジア、中南米、中東、アフリカ等）、関連企業情報などを掲載しています。 ・市場概要 ・HIVワクチンの市場動向 ・企業の競争状況、市場シェア ・HIVワクチンの種類別市場規模（フェーズI、フェーズII、フェーズIII） ・HIVワクチンの用途別市場規模（研究所、その他） ・HIVワクチンの北米市場規模2016-2027（アメリカ、カナダ） ・HIVワクチンのヨーロッパ市場規模2016-2027（ドイツ、フランス、イギリス等） ・HIVワクチンのアジア市場規模2016-2027（日本、中国、韓国、インド、東南アジア等） ・HIVワクチンの中南米市場規模2016-2027（メキシコ、ブラジル） ・HIVワクチンの中東・アフリカ市場規模2016-2027（トルコ、サウジアラビア等） ・主要企業情報（Argos Therapeutics、Bionor Pharma、Janssen Global Services、Genecure、Geovax,、Paxvax Corporation、Inovio Pharmaceuticals、Glaxosmithkline、Sanofi） ・結論

HIV Vaccine Market has been segmented on the basis of type which comprises of acute paronychia, chronic paronychia, candidal paronychia and pyogenic paronychia. On the basis of antibiotics, market is segmented into mupirocin ointment, fusidic acid ointment, gentamicin ointment, dicloxacillin and others.
Globally North America is the largest market for HIV vaccine market. The large size of the market can be attributed to higher adoption of various HIV vaccine trials coupled with presence of technologically and advancement.

Market Analysis and Insights: Global HIV Vaccines Market
The global HIV Vaccines market size is projected to reach US$ XX million by 2026, from US$ XX million in 2019, at a CAGR of XX% during 2021-2026.
With industry-standard accuracy in analysis and high data integrity, the report makes a brilliant attempt to unveil key opportunities available in the global HIV Vaccines market to help players in achieving a strong market position. Buyers of the report can access verified and reliable market forecasts, including those for the overall size of the global HIV Vaccines market in terms of revenue.
On the whole, the report proves to be an effective tool that players can use to gain a competitive edge over their competitors and ensure lasting success in the global HIV Vaccines market. All of the findings, data, and information provided in the report are validated and revalidated with the help of trustworthy sources. The analysts who have authored the report took a unique and industry-best research and analysis approach for an in-depth study of the global HIV Vaccines market.

Global HIV Vaccines Scope and Market Size
HIV Vaccines market is segmented by company, region (country), by Type, and by Application. Players, stakeholders, and other participants in the global HIV Vaccines market will be able to gain the upper hand as they use the report as a powerful resource. The segmental analysis focuses on revenue and forecast by Type and by Application in terms of revenue and forecast for the period 2016-2027.

Segment by Type
Phase I
Phase II
Phase III

Segment by Application
Research Institute
Other

By Region
North America
U.S.
Canada
Europe
Germany
France
U.K.
Italy
Russia
Nordic
Rest of Europe
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia
Rest of Asia
Latin America
Mexico
Brazil
Rest of Latin America
Middle East & Africa
Turkey
Saudi Arabia
UAE
Rest of MEA

By Company
Argos Therapeutics
Bionor Pharma
Janssen Global Services
Genecure
Geovax,
Paxvax Corporation
Inovio Pharmaceuticals
Glaxosmithkline
Sanofi

レポート目次

---

1 Report Overview
1.1 Study Scope
1.2 Market Analysis by Type
1.2.1 Global HIV Vaccines Market Size Growth Rate by Type: 2016 VS 2021 VS 2027
1.2.2 Phase I
1.2.3 Phase II
1.2.4 Phase III
1.3 Market by Application
1.3.1 Global HIV Vaccines Market Share by Application: 2016 VS 2021 VS 2027
1.3.2 Research Institute
1.3.3 Other
1.4 Study Objectives
1.5 Years Considered

2 Global Growth Trends
2.1 Global HIV Vaccines Market Perspective (2016-2027)
2.2 HIV Vaccines Growth Trends by Regions
2.2.1 HIV Vaccines Market Size by Regions: 2016 VS 2021 VS 2027
2.2.2 HIV Vaccines Historic Market Share by Regions (2016-2021)
2.2.3 HIV Vaccines Forecasted Market Size by Regions (2022-2027)
2.3 HIV Vaccines Industry Dynamic
2.3.1 HIV Vaccines Market Trends
2.3.2 HIV Vaccines Market Drivers
2.3.3 HIV Vaccines Market Challenges
2.3.4 HIV Vaccines Market Restraints

3 Competition Landscape by Key Players
3.1 Global Top HIV Vaccines Players by Revenue
3.1.1 Global Top HIV Vaccines Players by Revenue (2016-2021)
3.1.2 Global HIV Vaccines Revenue Market Share by Players (2016-2021)
3.2 Global HIV Vaccines Market Share by Company Type (Tier 1, Tier 2 and Tier 3)
3.3 Players Covered: Ranking by HIV Vaccines Revenue
3.4 Global HIV Vaccines Market Concentration Ratio
3.4.1 Global HIV Vaccines Market Concentration Ratio (CR5 and HHI)
3.4.2 Global Top 10 and Top 5 Companies by HIV Vaccines Revenue in 2020
3.5 HIV Vaccines Key Players Head office and Area Served
3.6 Key Players HIV Vaccines Product Solution and Service
3.7 Date of Enter into HIV Vaccines Market
3.8 Mergers & Acquisitions, Expansion Plans

4 HIV Vaccines Breakdown Data by Type
4.1 Global HIV Vaccines Historic Market Size by Type (2016-2021)
4.2 Global HIV Vaccines Forecasted Market Size by Type (2022-2027)

5 HIV Vaccines Breakdown Data by Application
5.1 Global HIV Vaccines Historic Market Size by Application (2016-2021)
5.2 Global HIV Vaccines Forecasted Market Size by Application (2022-2027)

6 North America
6.1 North America HIV Vaccines Market Size (2016-2027)
6.2 North America HIV Vaccines Market Size by Type
6.2.1 North America HIV Vaccines Market Size by Type (2016-2021)
6.2.2 North America HIV Vaccines Market Size by Type (2022-2027)
6.2.3 North America HIV Vaccines Market Size by Type (2016-2027)
6.3 North America HIV Vaccines Market Size by Application
6.3.1 North America HIV Vaccines Market Size by Application (2016-2021)
6.3.2 North America HIV Vaccines Market Size by Application (2022-2027)
6.3.3 North America HIV Vaccines Market Size by Application (2016-2027)
6.4 North America HIV Vaccines Market Size by Country
6.4.1 North America HIV Vaccines Market Size by Country (2016-2021)
6.4.2 North America HIV Vaccines Market Size by Country (2022-2027)
6.4.3 United States
6.4.3 Canada

7 Europe
7.1 Europe HIV Vaccines Market Size (2016-2027)
7.2 Europe HIV Vaccines Market Size by Type
7.2.1 Europe HIV Vaccines Market Size by Type (2016-2021)
7.2.2 Europe HIV Vaccines Market Size by Type (2022-2027)
7.2.3 Europe HIV Vaccines Market Size by Type (2016-2027)
7.3 Europe HIV Vaccines Market Size by Application
7.3.1 Europe HIV Vaccines Market Size by Application (2016-2021)
7.3.2 Europe HIV Vaccines Market Size by Application (2022-2027)
7.3.3 Europe HIV Vaccines Market Size by Application (2016-2027)
7.4 Europe HIV Vaccines Market Size by Country
7.4.1 Europe HIV Vaccines Market Size by Country (2016-2021)
7.4.2 Europe HIV Vaccines Market Size by Country (2022-2027)
7.4.3 Germany
7.4.4 France
7.4.5 U.K.
7.4.6 Italy
7.4.7 Russia
7.4.8 Nordic

8 Asia-Pacific
8.1 Asia-Pacific HIV Vaccines Market Size (2016-2027)
8.2 Asia-Pacific HIV Vaccines Market Size by Type
8.2.1 Asia-Pacific HIV Vaccines Market Size by Type (2016-2021)
8.2.2 Asia-Pacific HIV Vaccines Market Size by Type (2022-2027)
8.2.3 Asia-Pacific HIV Vaccines Market Size by Type (2016-2027)
8.3 Asia-Pacific HIV Vaccines Market Size by Application
8.3.1 Asia-Pacific HIV Vaccines Market Size by Application (2016-2021)
8.3.2 Asia-Pacific HIV Vaccines Market Size by Application (2022-2027)
8.3.3 Asia-Pacific HIV Vaccines Market Size by Application (2016-2027)
8.4 Asia-Pacific HIV Vaccines Market Size by Region
8.4.1 Asia-Pacific HIV Vaccines Market Size by Region (2016-2021)
8.4.2 Asia-Pacific HIV Vaccines Market Size by Region (2022-2027)
8.4.3 China
8.4.4 Japan
8.4.5 South Korea
8.4.6 Southeast Asia
8.4.7 India
8.4.8 Australia

9 Latin America
9.1 Latin America HIV Vaccines Market Size (2016-2027)
9.2 Latin America HIV Vaccines Market Size by Type
9.2.1 Latin America HIV Vaccines Market Size by Type (2016-2021)
9.2.2 Latin America HIV Vaccines Market Size by Type (2022-2027)
9.2.3 Latin America HIV Vaccines Market Size by Type (2016-2027)
9.3 Latin America HIV Vaccines Market Size by Application
9.3.1 Latin America HIV Vaccines Market Size by Application (2016-2021)
9.3.2 Latin America HIV Vaccines Market Size by Application (2022-2027)
9.3.3 Latin America HIV Vaccines Market Size by Application (2016-2027)
9.4 Latin America HIV Vaccines Market Size by Country
9.4.1 Latin America HIV Vaccines Market Size by Country (2016-2021)
9.4.2 Latin America HIV Vaccines Market Size by Country (2022-2027)
9.4.3 Mexico
9.4.4 Brazil

10 Middle East & Africa
10.1 Middle East & Africa HIV Vaccines Market Size (2016-2027)
10.2 Middle East & Africa HIV Vaccines Market Size by Type
10.2.1 Middle East & Africa HIV Vaccines Market Size by Type (2016-2021)
10.2.2 Middle East & Africa HIV Vaccines Market Size by Type (2022-2027)
10.2.3 Middle East & Africa HIV Vaccines Market Size by Type (2016-2027)
10.3 Middle East & Africa HIV Vaccines Market Size by Application
10.3.1 Middle East & Africa HIV Vaccines Market Size by Application (2016-2021)
10.3.2 Middle East & Africa HIV Vaccines Market Size by Application (2022-2027)
10.3.3 Middle East & Africa HIV Vaccines Market Size by Application (2016-2027)
10.4 Middle East & Africa HIV Vaccines Market Size by Country
10.4.1 Middle East & Africa HIV Vaccines Market Size by Country (2016-2021)
10.4.2 Middle East & Africa HIV Vaccines Market Size by Country (2022-2027)
10.4.3 Turkey
10.4.4 Saudi Arabia
10.4.5 UAE

11 Key Players Profiles
11.1 Argos Therapeutics
11.1.1 Argos Therapeutics Company Details
11.1.2 Argos Therapeutics Business Overview
11.1.3 Argos Therapeutics HIV Vaccines Introduction
11.1.4 Argos Therapeutics Revenue in HIV Vaccines Business (2016-2021)
11.1.5 Argos Therapeutics Recent Development
11.2 Bionor Pharma
11.2.1 Bionor Pharma Company Details
11.2.2 Bionor Pharma Business Overview
11.2.3 Bionor Pharma HIV Vaccines Introduction
11.2.4 Bionor Pharma Revenue in HIV Vaccines Business (2016-2021)
11.2.5 Bionor Pharma Recent Development
11.3 Janssen Global Services
11.3.1 Janssen Global Services Company Details
11.3.2 Janssen Global Services Business Overview
11.3.3 Janssen Global Services HIV Vaccines Introduction
11.3.4 Janssen Global Services Revenue in HIV Vaccines Business (2016-2021)
11.3.5 Janssen Global Services Recent Development
11.4 Genecure
11.4.1 Genecure Company Details
11.4.2 Genecure Business Overview
11.4.3 Genecure HIV Vaccines Introduction
11.4.4 Genecure Revenue in HIV Vaccines Business (2016-2021)
11.4.5 Genecure Recent Development
11.5 Geovax,
11.5.1 Geovax, Company Details
11.5.2 Geovax, Business Overview
11.5.3 Geovax, HIV Vaccines Introduction
11.5.4 Geovax, Revenue in HIV Vaccines Business (2016-2021)
11.5.5 Geovax, Recent Development
11.6 Paxvax Corporation
11.6.1 Paxvax Corporation Company Details
11.6.2 Paxvax Corporation Business Overview
11.6.3 Paxvax Corporation HIV Vaccines Introduction
11.6.4 Paxvax Corporation Revenue in HIV Vaccines Business (2016-2021)
11.6.5 Paxvax Corporation Recent Development
11.7 Inovio Pharmaceuticals
11.7.1 Inovio Pharmaceuticals Company Details
11.7.2 Inovio Pharmaceuticals Business Overview
11.7.3 Inovio Pharmaceuticals HIV Vaccines Introduction
11.7.4 Inovio Pharmaceuticals Revenue in HIV Vaccines Business (2016-2021)
11.7.5 Inovio Pharmaceuticals Recent Development
11.8 Glaxosmithkline
11.8.1 Glaxosmithkline Company Details
11.8.2 Glaxosmithkline Business Overview
11.8.3 Glaxosmithkline HIV Vaccines Introduction
11.8.4 Glaxosmithkline Revenue in HIV Vaccines Business (2016-2021)
11.8.5 Glaxosmithkline Recent Development
11.9 Sanofi
11.9.1 Sanofi Company Details
11.9.2 Sanofi Business Overview
11.9.3 Sanofi HIV Vaccines Introduction
11.9.4 Sanofi Revenue in HIV Vaccines Business (2016-2021)
11.9.5 Sanofi Recent Development

12 Analyst’s Viewpoints/Conclusions

13 Appendix
13.1 Research Methodology
13.1.1 Methodology/Research Approach
13.1.2 Data Source
13.2 Disclaimer
13.3 Author Details

List of Tables
Table 1. Global HIV Vaccines Market Size Growth Rate by Type (US$ Million):2016 VS 2021 VS 2027
Table 2. Key Players of Phase I
Table 3. Key Players of Phase II
Table 4. Key Players of Phase III
Table 5. Global HIV Vaccines Market Size Growth by Application (US$ Million): 2016 VS 2021 VS 2027
Table 6. Global HIV Vaccines Market Size by Regions (US$ Million): 2016 VS 2021 VS 2027
Table 7. Global HIV Vaccines Market Size by Regions (2016-2021) & (US$ Million)
Table 8. Global HIV Vaccines Market Share by Regions (2016-2021)
Table 9. Global HIV Vaccines Forecasted Market Size by Regions (2022-2027) & (US$ Million)
Table 10. Global HIV Vaccines Market Share by Regions (2022-2027)
Table 11. HIV Vaccines Market Trends
Table 12. HIV Vaccines Market Drivers
Table 13. HIV Vaccines Market Challenges
Table 14. HIV Vaccines Market Restraints
Table 15. Global HIV Vaccines Revenue by Players (2016-2021) & (US$ Million)
Table 16. Global HIV Vaccines Market Share by Players (2016-2021)
Table 17. Global Top HIV Vaccines Players by Company Type (Tier 1, Tier 2 and Tier 3) (based on the Revenue in HIV Vaccines as of 2020)
Table 18. Ranking of Global Top HIV Vaccines Companies by Revenue (US$ Million) in 2020
Table 19. Global 5 Largest Players Market Share by HIV Vaccines Revenue (CR5 and HHI) & (2016-2021)
Table 20. Key Players Headquarters and Area Served
Table 21. Key Players HIV Vaccines Product Solution and Service
Table 22. Date of Enter into HIV Vaccines Market
Table 23. Mergers & Acquisitions, Expansion Plans
Table 24. Global HIV Vaccines Market Size by Type (2016-2021) (US$ Million)
Table 25. Global HIV Vaccines Revenue Market Share by Type (2016-2021)
Table 26. Global HIV Vaccines Forecasted Market Size by Type (2022-2027) (US$ Million)
Table 27. Global HIV Vaccines Revenue Market Share by Type (2022-2027) & (US$ Million)
Table 28. Global HIV Vaccines Market Size Share by Application (2016-2021) & (US$ Million)
Table 29. Global HIV Vaccines Revenue Market Share by Application (2016-2021)
Table 30. Global HIV Vaccines Forecasted Market Size by Application (2022-2027) (US$ Million)
Table 31. Global HIV Vaccines Revenue Market Share by Application (2022-2027) & (US$ Million)
Table 32. North America HIV Vaccines Market Size by Type (2016-2021) (US$ Million)
Table 33. North America HIV Vaccines Market Size by Type (2022-2027) & (US$ Million)
Table 34. North America HIV Vaccines Market Size by Application (2016-2021) (US$ Million)
Table 35. North America HIV Vaccines Market Size by Application (2022-2027) & (US$ Million)
Table 36. North America HIV Vaccines Market Size by Country (2016-2021) & (US$ Million)
Table 37. North America HIV Vaccines Market Size by Country (2022-2027) & (US$ Million)
Table 38. Europe HIV Vaccines Market Size by Type (2016-2021) (US$ Million)
Table 39. Europe HIV Vaccines Market Size by Type (2022-2027) & (US$ Million)
Table 40. Europe HIV Vaccines Market Size by Application (2016-2021) (US$ Million)
Table 41. Europe HIV Vaccines Market Size by Application (2022-2027) & (US$ Million)
Table 42. Europe HIV Vaccines Market Size by Country (2016-2021) & (US$ Million)
Table 43. Europe HIV Vaccines Market Size by Country (2022-2027) & (US$ Million)
Table 44. Asia-Pacific HIV Vaccines Market Size by Type (2016-2021) (US$ Million)
Table 45. Asia-Pacific HIV Vaccines Market Size by Type (2022-2027) & (US$ Million)
Table 46. Asia-Pacific HIV Vaccines Market Size by Application (2016-2021) (US$ Million)
Table 47. Asia-Pacific HIV Vaccines Market Size by Application (2022-2027) & (US$ Million)
Table 48. Asia-Pacific HIV Vaccines Market Size by Region (2016-2021) & (US$ Million)
Table 49. Asia-Pacific HIV Vaccines Market Size by Region (2022-2027) & (US$ Million)
Table 50. Latin America HIV Vaccines Market Size by Type (2016-2021) (US$ Million)
Table 51. Latin America HIV Vaccines Market Size by Type (2022-2027) & (US$ Million)
Table 52. Latin America HIV Vaccines Market Size by Application (2016-2021) (US$ Million)
Table 53. Latin America HIV Vaccines Market Size by Application (2022-2027) & (US$ Million)
Table 54. Latin America HIV Vaccines Market Size by Country (2016-2021) & (US$ Million)
Table 55. Latin America HIV Vaccines Market Size by Country (2022-2027) & (US$ Million)
Table 56. Middle East & Africa HIV Vaccines Market Size by Type (2016-2021) (US$ Million)
Table 57. Middle East & Africa HIV Vaccines Market Size by Type (2022-2027) & (US$ Million)
Table 58. Middle East & Africa HIV Vaccines Market Size by Application (2016-2021) (US$ Million)
Table 59. Middle East & Africa HIV Vaccines Market Size by Application (2022-2027) & (US$ Million)
Table 60. Middle East & Africa HIV Vaccines Market Size by Country (2016-2021) & (US$ Million)
Table 61. Middle East & Africa HIV Vaccines Market Size by Country (2022-2027) & (US$ Million)
Table 62. Argos Therapeutics Company Details
Table 63. Argos Therapeutics Business Overview
Table 64. Argos Therapeutics HIV Vaccines Product
Table 65. Argos Therapeutics Revenue in HIV Vaccines Business (2016-2021) & (US$ Million)
Table 66. Argos Therapeutics Recent Development
Table 67. Bionor Pharma Company Details
Table 68. Bionor Pharma Business Overview
Table 69. Bionor Pharma HIV Vaccines Product
Table 70. Bionor Pharma Revenue in HIV Vaccines Business (2016-2021) & (US$ Million)
Table 71. Bionor Pharma Recent Development
Table 72. Janssen Global Services Company Details
Table 73. Janssen Global Services Business Overview
Table 74. Janssen Global Services HIV Vaccines Product
Table 75. Janssen Global Services Revenue in HIV Vaccines Business (2016-2021) & (US$ Million)
Table 76. Janssen Global Services Recent Development
Table 77. Genecure Company Details
Table 78. Genecure Business Overview
Table 79. Genecure HIV Vaccines Product
Table 80. Genecure Revenue in HIV Vaccines Business (2016-2021) & (US$ Million)
Table 81. Genecure Recent Development
Table 82. Geovax, Company Details
Table 83. Geovax, Business Overview
Table 84. Geovax, HIV Vaccines Product
Table 85. Geovax, Revenue in HIV Vaccines Business (2016-2021) & (US$ Million)
Table 86. Geovax, Recent Development
Table 87. Paxvax Corporation Company Details
Table 88. Paxvax Corporation Business Overview
Table 89. Paxvax Corporation HIV Vaccines Product
Table 90. Paxvax Corporation Revenue in HIV Vaccines Business (2016-2021) & (US$ Million)
Table 91. Paxvax Corporation Recent Development
Table 92. Inovio Pharmaceuticals Company Details
Table 93. Inovio Pharmaceuticals Business Overview
Table 94. Inovio Pharmaceuticals HIV Vaccines Product
Table 95. Inovio Pharmaceuticals Revenue in HIV Vaccines Business (2016-2021) & (US$ Million)
Table 96. Inovio Pharmaceuticals Recent Development
Table 97. Glaxosmithkline Company Details
Table 98. Glaxosmithkline Business Overview
Table 99. Glaxosmithkline Revenue in HIV Vaccines Business (2016-2021) & (US$ Million)
Table 100. Glaxosmithkline Recent Development
Table 101. Sanofi Company Details
Table 102. Sanofi Business Overview
Table 103. Sanofi HIV Vaccines Product
Table 104. Sanofi Revenue in HIV Vaccines Business (2016-2021) & (US$ Million)
Table 105. Sanofi Recent Development
Table 106. Research Programs/Design for This Report
Table 107. Key Data Information from Secondary Sources
Table 108. Key Data Information from Primary Sources
List of Figures
Figure 1. Global HIV Vaccines Market Share by Type: 2020 VS 2027
Figure 2. Phase I Features
Figure 3. Phase II Features
Figure 4. Phase III Features
Figure 5. Global HIV Vaccines Market Share by Application: 2020 VS 2027
Figure 6. Research Institute Case Studies
Figure 7. Other Case Studies
Figure 8. HIV Vaccines Report Years Considered
Figure 9. Global HIV Vaccines Market Size (US$ Million), Year-over-Year: 2016-2027
Figure 10. Global HIV Vaccines Market Size (US$ Million), 2016 VS 2021 VS 2027
Figure 11. Global HIV Vaccines Market Share by Regions: 2020 VS 2027
Figure 12. Global HIV Vaccines Market Share by Regions (2022-2027)
Figure 13. Global HIV Vaccines Market Share by Players in 2020
Figure 14. Global Top HIV Vaccines Players by Company Type (Tier 1, Tier 2 and Tier 3) (based on the Revenue in HIV Vaccines as of 2020
Figure 15. The Top 10 and 5 Players Market Share by HIV Vaccines Revenue in 2020
Figure 16. Global HIV Vaccines Revenue Market Share by Type (2016-2021)
Figure 17. Global HIV Vaccines Revenue Market Share by Type (2022-2027)
Figure 18. North America HIV Vaccines Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 19. North America HIV Vaccines Market Share by Type (2016-2027)
Figure 20. North America HIV Vaccines Market Share by Application (2016-2027)
Figure 21. North America HIV Vaccines Market Share by Country (2016-2027)
Figure 22. United States HIV Vaccines Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 23. Canada HIV Vaccines Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 24. Europe HIV Vaccines Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 25. Europe HIV Vaccines Market Share by Type (2016-2027)
Figure 26. Europe HIV Vaccines Market Share by Application (2016-2027)
Figure 27. Europe HIV Vaccines Market Share by Country (2016-2027)
Figure 28. Germany HIV Vaccines Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 29. France HIV Vaccines Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 30. U.K. HIV Vaccines Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 31. Italy HIV Vaccines Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 32. Russia HIV Vaccines Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 33. Nordic HIV Vaccines Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 34. Asia-Pacific HIV Vaccines Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 35. Asia-Pacific HIV Vaccines Market Share by Type (2016-2027)
Figure 36. Asia-Pacific HIV Vaccines Market Share by Application (2016-2027)
Figure 37. Asia-Pacific HIV Vaccines Market Share by Region (2016-2027)
Figure 38. China HIV Vaccines Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 39. Japan HIV Vaccines Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 40. South Korea HIV Vaccines Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 41. Southeast Asia HIV Vaccines Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 42. India HIV Vaccines Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 43. Australia HIV Vaccines Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 44. Latin America HIV Vaccines Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 45. Latin America HIV Vaccines Market Share by Type (2016-2027)
Figure 46. Latin America HIV Vaccines Market Share by Application (2016-2027)
Figure 47. Latin America HIV Vaccines Market Share by Country (2016-2027)
Figure 48. Mexico HIV Vaccines Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 49. Brazil HIV Vaccines Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 50. Middle East & Africa HIV Vaccines Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 51. Middle East & Africa HIV Vaccines Market Share by Type (2016-2027)
Figure 52. Middle East & Africa HIV Vaccines Market Share by Application (2016-2027)
Figure 53. Middle East & Africa HIV Vaccines Market Share by Country (2016-2027)
Figure 54. Turkey HIV Vaccines Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 55. Saudi Arabia HIV Vaccines Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 56. UAE HIV Vaccines Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 57. Argos Therapeutics Revenue Growth Rate in HIV Vaccines Business (2016-2021)
Figure 58. Bionor Pharma Revenue Growth Rate in HIV Vaccines Business (2016-2021)
Figure 59. Janssen Global Services Revenue Growth Rate in HIV Vaccines Business (2016-2021)
Figure 60. Genecure Revenue Growth Rate in HIV Vaccines Business (2016-2021)
Figure 61. Geovax, Revenue Growth Rate in HIV Vaccines Business (2016-2021)
Figure 62. Paxvax Corporation Revenue Growth Rate in HIV Vaccines Business (2016-2021)
Figure 63. Inovio Pharmaceuticals Revenue Growth Rate in HIV Vaccines Business (2016-2021)
Figure 64. Glaxosmithkline Revenue Growth Rate in HIV Vaccines Business (2016-2021)
Figure 65. Sanofi Revenue Growth Rate in HIV Vaccines Business (2016-2021)
Figure 66. Bottom-up and Top-down Approaches for This Report
Figure 67. Data Triangulation
Figure 68. Key Executives Interviewed

---